Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8765230 | 1.00 | DRD2 (0.55) | DRD2DRD1KCNH2HCRTR1HCRTR2 | |
| SCHEMBL20170872 | 1.00 | DRD2 (0.55) | DRD2DRD1KCNH2HCRTR1HCRTR2 | |
| SCHEMBL11051922 | 0.89 | DRD2 (0.54) | DRD2DRD1KCNH2HCRTR1HCRTR2 | |
| SCHEMBL11926150 | 0.88 | DRD2 (0.59) | DRD2DRD1KCNH2HCRTR1HCRTR2 | |
| SCHEMBL20170801 | 0.86 | DRD2 (0.60) | DRD2DRD1KCNH2BCHEACHE | |
| SCHEMBL20170769 | 0.86 | DRD2 (0.60) | DRD2DRD1KCNH2BCHEACHE | |
| SCHEMBL20170661 | 0.85 | DRD2 (0.56) | DRD2DRD1KCNH2HCRTR1HCRTR2 | |
| SCHEMBL11052814 | 0.85 | DRD2 (0.56) | DRD2DRD1KCNH2HCRTR1HCRTR2 | |
| SCHEMBL8764588 | 0.85 | DRD2 (0.56) | DRD2DRD1KCNH2HCRTR1HCRTR2 | |
| SCHEMBL10222658 | 0.85 | DRD2 (0.56) | DRD2DRD1KCNH2HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9527858-B2 | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers | MALLINCKRODT LLC (US) | 2016-12-27 | — | — | US | disclosed |
| US-9518062-B2 | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers | MALLINCKRODT LLC (US) | 2016-12-13 | — | — | US | disclosed |
| US-20140370005-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN PHOTOTHERAPY AND IN TREATMENT OF OCULAR NEOVASCULAR DISEASE AND CANCERS | SpecGx LLC | 2014-12-18 | — | — | US | disclosed |
| US-20140370006-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN PHOTOTHERAPY AND IN TREATMENT OF OCULAR NEOVASCULAR DISEASE AND CANCERS | SpecGx LLC | 2014-12-18 | — | — | US | disclosed |
| US-8829020-B2 | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers | MALLINCKRODT LLC (US) | 2014-09-09 | — | — | US | disclosed |
| US-20120129879-A1 | Compounds and Compositions for Use in Phototherapy and in Treatment of Ocular Neovascular Disease and Cancers | MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY | 2012-05-24 | — | — | US | disclosed |
| WO-2011009020-A2 | COMPOUNDS AND COMPOSITIONS FOR USE IN PHOTOTHERAPY AND IN TREATMENT OF OCULAR NEOVASCULAR DISEASE AND CANCERS | MALLINCKRODT INC. (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140370006-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN PHOTOTHERAPY AND IN TREATMENT OF OCULAR NEOVASCULAR DISEASE AND CANCERS | VEGFA, OPRL1, OGFR | DRD2 587/4885DRD1 644/4885KCNH2 4425/4885 |
| US-20140370005-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN PHOTOTHERAPY AND IN TREATMENT OF OCULAR NEOVASCULAR DISEASE AND CANCERS | VEGFA, OPRL1, OGFR | DRD2 587/4885DRD1 644/4885KCNH2 4425/4885 |
| US-20120129879-A1 | Compounds and Compositions for Use in Phototherapy and in Treatment of Ocular Neovascular Disease and Cancers | VEGFA, OPRL1, OGFR | DRD2 587/4885DRD1 644/4885KCNH2 4425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.